대한이식학회지 (Korean Journal of Transplantation)

  • 제32권4호
  • /
  • Pages.108-112
  • /
  • 2018
  • /
  • 2671-8790(pISSN)
  • /
  • 2671-8804(eISSN)
대한이식학회 (The Korean Society For Transplantation)
권호 표지
DOI QR코드

DOI QR Code

Donor Specific Antibody Negative Antibody-Mediated Rejection after ABO Incompatible Liver Transplantation

  • Lee, Boram (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Ahn, Soomin (Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Haeryoung (Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Han, Ho-Seong (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Yoon, Yoo-Seok (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Cho, Jai Young (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Choi, Young Rok (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • 투고 : 2018.07.06
  • 심사 : 2018.09.13
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Antibody-mediated rejection (AMR) is a major complication after ABO-incompatible liver transplantation. According to the 2016 Banff Working Group on Liver Allograft Criteria for the diagnosis of acute AMR, a positive serum donor specific antibody (DSA) is needed. On the other hand, the clinical significance of the histological findings of AMR in the absence of DSA is unclear. This paper describes a 57-year-old man (blood type, O+) who suffered from hepatitis B virus cirrhosis with hepatocellular carcinoma. Pre-operative DSA and cross-matching were negative. After transplantation, despite the improvement of the liver function, acute AMR was observed in the protocol biopsy on postoperative day 7; the cluster of differentiation 19+ (CD19+) count was 0% and anti-ABO antibody titers were 1:2. This paper presents the allograft injury like AMR in the absence of DSA after ABOi living donor liver transplantation with low titers of anti-ABO antibody and depleted serum CD19+ B cells.

키워드

참고문헌

  1. Cooper DK. A brief history of cross-species organ transplantation. Proc (Bayl Univ Med Cent) 2012;25:49-57. https://doi.org/10.1080/08998280.2012.11928783
  2. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990;336:519-23. https://doi.org/10.1016/0140-6736(90)92082-S
  3. Usuda M, Fujimori K, Koyamada N, Fukumori T, Sekiguchi S, Kawagishi N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005;79:12-6. https://doi.org/10.1097/01.TP.0000149337.40911.E4
  4. Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008;47:143-52.
  5. Demetris AJ, Bellamy C, Hubscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant 2016;16:2816-35. https://doi.org/10.1111/ajt.13909
  6. Krishnan NS, Zehnder D, Briggs D, Higgins R. Human leukocyte antigen antibody incompatible renal transplantation. Indian J Nephrol 2012;22:409-14. https://doi.org/10.4103/0971-4065.106029
  7. Song GW, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant 2016;16:157-70. https://doi.org/10.1111/ajt.13444
  8. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008;14:554-62. https://doi.org/10.1002/lt.21408
  9. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011;17:357-68. https://doi.org/10.1002/lt.22233
  10. O'Leary JG, Kaneku H, Jennings LW, Banuelos N, Susskind BM, Terasaki PI, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19:973-80. https://doi.org/10.1002/lt.23687
  11. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012;12:1504-10. https://doi.org/10.1111/j.1600-6143.2012.03995.x
  12. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013;13:1541-8. https://doi.org/10.1111/ajt.12212
  13. Zou Y, Heinemann FM, Grosse-Wilde H, Sireci G, Wang Z, Lavingia B, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006;67:230-7. https://doi.org/10.1016/j.humimm.2006.02.017
  14. Alten TA, Negm AA, Voigtlander T, Jaeckel E, Lehner F, Brauner C, et al. Safety and performance of liver biopsies in liver transplant recipients. Clin Transplant 2014;28:585-9. https://doi.org/10.1111/ctr.12352
  15. O'Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014;20:218-27. https://doi.org/10.1002/lt.23788